Three Lakes Foundation and the American College of Chest Physicians (CHEST) recently announced their collaboration on a multiphase educational initiative aiming to reduce the time it takes to diagnose patients with Interstitial Lung Diseases (ILD).
Omicron linked to rise in croup in babies; TB vaccine improves immune response to coronavirusAnnals of Neurology, Babies, Bacillus Calmette-Guerin (BCG) Vaccine, Coronavirus, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Studies, Croup, Data, Hospitalized COVID-19 Patients, Immune Response, Omicron (B.1.1.529) (South Africa), Pediatrics, R&D, Research, Respiratory Conditions, Toddlers, Tuberculosis, Ventilators
The Omicron variant of the coronavirus is causing a dramatic rise in cases of croup, a dangerous respiratory condition usually seen in babies and toddlers, new data suggest. Additionally, new research sheds light on how a tuberculosis vaccine might help protect against COVID-19.
AstraZeneca said on Nov. 1 the company will transfer global rights for respiratory medicines Eklira and Duaklir to Covis Pharma Group for $270 million, as the Anglo-Swedish drugmaker looks to offload its older portfolio of medicines.
Pfizer announced on Sept. 2 the dosing of the first patients in a Phase III trial assessing a single dose of the company’s investigational RSV bivalent prefusion F subunit vaccine candidate (RSVpreF) in adults ages 60 and older. One day earlier, Pfizer announced the initiation of a Phase II/III clinical study of 1,140 participants for an oral pill expected to be used in a broad population of Covid patients.
Moderna will construct a state-of-the-art manufacturing facility in Canada in order to provide direct access to mRNA vaccines for the Covid-19 pandemic, as well as future viral threats and respiratory viruses.
Pfizer Inc.’s oral rheumatoid arthritis drug Xeljanz reduced death or respiratory failure in hospitalized Covid-19 patients with pneumonia in Brazil, meeting the study’s main goal.
A readout from a Phase IIb/III trial showed intravenous RLF-100 (aviptadil) met the primary endpoint of improving survival and recovery at 60 days post-treatment for respiratory failure in critically ill patients with Covid-19, bolstering the case for sponsors NeuroRx and Relief Therapeutics to reapply for emergency use authorization (EUA).
Enalare Therapeutics Inc., dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced the completed formation of the clinical stage biopharmaceutical company’s scientific advisory board.
As many as eight gorillas at the San Diego Zoo Safari Park were presumed to have contracted Covid-19 from a human handler after one of the animals tested positive, marking the first known transmission of the virus to apes, zoo officials said.
Clinical diagnostics company Novacyt, one of many healthcare companies whose shares have surged during the pandemic, launched a test to differentiate between Covid-19 and common winter diseases.